~Patient Recruitment Closed~LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in its Phase 2/3 clinical trial, COMBAT-ALS, evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 patients have been randomized across two treatment ...

São Paulo, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Embraer S.A. (“Embraer”) (NYSE: ERJ) announces that: Morgan Stanley & Co. LLC (the “Offeror”), with the consent of Embraer and Embraer Netherlands Finance B.V. (“Embraer Finance”) has commenced cash tender offers (each offer, an “Offer” and, collectively, the “Offers”) of outstanding (i) 6.950% senior unsecured guaranteed notes due 2028 (the “2028 Notes”) and (ii) 7.000% senior unsecured guaranteed notes due 2030 (the “2030 Notes” and, together with the 2028 Not ...

Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companiesSUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades of experience ...

Core Viewpoint - Corbus Pharmaceuticals is hosting a KOL event to discuss dose optimization data from its Phase 1/2 clinical trial of CRB-701, targeting advanced solid tumors with high Nectin-4 expression [1][3]. Group 1: Event Details - The KOL event will take place on October 19, 2025, at the Berlin Germany Marriott, starting at 10 AM CEST [2]. - The event will include insights from leading experts in head and neck squamous cell carcinoma (HNSCC) and a live Q&A session [2]. Group 2: Clinical Trial Information - The ongoing clinical trial (NCT06265727) is evaluating the safety, pharmacokinetics, and efficacy of CRB-701 in patients with advanced solid tumors, primarily focusing on HNSCC and cervical cancer [3]. - Data from over 100 participants will be presented, highlighting the trial's significance in the oncology field [1]. Group 3: About CRB-701 - CRB-701 is a next-generation antibody drug conjugate (ADC) that targets Nectin-4, utilizing a cleavable linker and a drug antibody ratio of 2, with monomethyl auristatin E as the payload [7][8]. - Nectin-4 is recognized as a clinically validated tumor-associated antigen in urothelial cancer [8]. Group 4: Company Overview - Corbus Pharmaceuticals is a clinical stage oncology and obesity company focused on innovative scientific approaches to treat serious illnesses [9]. - The company's pipeline includes CRB-701, CRB-601 (an anti-integrin monoclonal antibody), and CRB-913 (a CB1 receptor inverse agonist for obesity) [9].

Accessibility StatementSkip Navigation Forward-Looking StatementsThis communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address future business and financial events, conditions, expectations, plans or ambitions, and often include, but are not limited to, words such as "believe," "expect," "may," ...

Study led by CureShankAims to characterize the direct and indirect burden of PMS to patients, caregivers, and US healthcare system MADRID and CAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, is proud to announce its participation as a sponsor of the first-ever Phelan-McDermid syndrome (PMS) burden of illness study. The study is led by CureShank, a research advocacy organ ...

SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in the Defense, National Security and Global Markets, announced today that it will be added to the S&P MidCap 400 Index, transitioning from the S&P SmallCap 600 Index. The move reflects Kratos’ continued growth, performance, and market recognition as the company scales its leadership in unmanned systems, hypersonics, space, propulsion, and other national security solutions. Placement ...

VANCOUVER, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Aventis Energy (“Aventis” or the “Company”) (CSE:AVE | FRA:C0O0 | OTC: VBAMF) is pleased to announce an update from its 2025 exploration program at the Corvo Uranium Project (“Corvo”, or the “Project”), currently under a three-year earn-in option agreement with Standard Uranium Ltd. (“Standard”) (CSE: STND). From July 4 to July 16, 2025, the Company completed a detailed mapping and sampling program across historical uranium showings and zones o ...

Accelerating Treep Mobility's Transformation from Fuel-Powered Vehicles to EVs Following Successful Pilot Deployment SHANGHAI , Sept. 22, 2025 /PRNewswire/ -- U Power Limited (Nasdaq: UCAR) (the "Company" or "U Power"), a provider of AI-powered solutions for next-generation energy grids and intelligent transportation systems, building on its proprietary UOTTATM electric vehicle (EV) battery-swapping technology, today announced that it has signed an initial sales agreement with Treep Mobility Group S.A.C. ...

                                                                          PICKERING, Ontario – TheNewswire - September 22, 2025 - Renforth Resources Inc. (CSE: RFR) (OTC: RFHRF) (FSE: 9RR) (“Renforth” or the “Company”), is pleased to advise shareholders that Renforth will have a booth at the Munich Mining Conference, October 3rd and 4th, and presenting to conference attendees on October 4th at 10am local time. The conference has 109 companies attending and more than 1,000 individual investors registered to ...